A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection

This study has been completed.

Sponsored by:	Adherex Technologies, Inc.
Information provided by:	Adherex Technologies, Inc.
ClinicalTrials.gov Identifier:	NCT00264446

Purpose

5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will examine the kinetics of inhibition and recovery of the metabolic pathways for fluoropyrimidines in subjects who receive a single oral dose of ADH300004, and may allow optimization of oral 5 FU dosing to subjects in future studies.

Condition	Intervention	Phase
Neoplasms	Drug: ADH300004	Phase I

MedlinePlus related topics: Cancer Colorectal Cancer

Drug Information available for: 5-Ethynyluracil Uridine Thymidine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment
Official Title:	Phase 1 Study of the Evaluation of Dihydropyrimidine Dehydrogenase (DPD), Uridine Phosphorylase (UP), Orotate Phosphoribosyl Transferase (OPRT), and Thymidine Phosphorylase (TP) Activity in Tissue Resected From Subjects Undergoing Planned Resection of Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection, Following Administration of Oral ADH300004 (Adherex Protocol Number AHX-03-101)

Eligibility

Ages Eligible for Study:	19 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Signed written informed consent
> or = 19 years of age
Patients with histologically confirmed:
- primary or metastatic (known or suspected) colorectal carcinoma requiring planned surgical resection with hepatic biopsy and systemic chemotherapy , or
- primary or metastatic neoplastic disease within the liver from any origin requiring planned surgical resection and systemic chemotherapy
Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing

Exclusion Criteria:

Lack of known or suspected metastatic disease in the liver
Known DPD deficiency
Severe infection
Inability to take oral medication
The need for treatment with any fluoropyrimidine within 8 weeks of any ADH300004 dose
Stroke, major surgery, or other major tissue injury within 30 days before study entry

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00264446

Locations

United States, Alabama
UAB - Division of Surgery
Birmingham, Alabama, United States, 35294-3300

Sponsors and Collaborators

Adherex Technologies, Inc.

Investigators

Principal Investigator:

Martin Heslin, MD

University of Alabama at Birmingham

More Information

Adherex Technologies Inc. Corporate Homepage This link exits the ClinicalTrials.gov site

Study ID Numbers:	Adherex Protocol # AHX-03-101
Study First Received:	December 12, 2005
Last Updated:	August 3, 2007
ClinicalTrials.gov Identifier:	NCT00264446
Health Authority:	United States: Food and Drug Administration

Keywords provided by Adherex Technologies, Inc.:

Cancer; Tumors; Neoplasms; Anticarcinogenic Agents; Antineoplastic Agents;
Dihydrouracil dehydrogenase (NADP); Colorectal Carcinoma; Liver Cancer

Study placed in the following topic categories:

Dihydropyrimidine dehydrogenase deficiency
Digestive System Neoplasms
Gastrointestinal Diseases
Colonic Diseases
5-ethynyluracil
Liver neoplasms
Dihydropyrimidine Dehydrogenase Deficiency
Intestinal Diseases

Rectal Diseases
Intestinal Neoplasms
Carcinoma
Liver Neoplasms
Digestive System Diseases
Dihydrouracil Dehydrogenase (NADP)
Gastrointestinal Neoplasms
Colorectal Neoplasms

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009